13.41
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$13.44
Offen:
$13.33
24-Stunden-Volumen:
8.61M
Relative Volume:
0.85
Marktkapitalisierung:
$15.44B
Einnahmen:
$14.29B
Nettoeinkommen (Verlust:
$-3.51B
KGV:
-4.5299
EPS:
-2.9603
Netto-Cashflow:
$1.85B
1W Leistung:
+3.47%
1M Leistung:
-5.30%
6M Leistung:
+32.38%
1J Leistung:
+75.98%
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
VTRS
Viatris Inc
|
13.41 | 15.47B | 14.29B | -3.51B | 1.85B | -2.9603 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
118.26 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
9.92 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
559.65 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Hochstufung | UBS | Neutral → Buy |
| 2026-01-16 | Hochstufung | Argus | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-06-06 | Eingeleitet | Goldman | Neutral |
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Viatris Inc (VIA.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris (VTRS) price target increased by 10.80% to 15.70 - MSN
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris (VTRS) 2026 proxy details $14.3B revenue, board refresh and key votes - Stock Titan
(VTRS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight - Investing.com
Viatris Inc. (VTRS) Stock Forecasts - finance.yahoo.com
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Named a Great Place To Work in India for the Fifth Consecutive Year - businesswireindia.com
Is Effexor’s First-in-Class GAD Approval in Japan Altering The Investment Case For Viatris (VTRS)? - simplywall.st
VTRS PE Ratio & Valuation, Is VTRS Overvalued - Intellectia AI
Viatris sets long-term targets ahead of investor event - MSN
ACC26 conference visit sees Viatris stock decline amid persistent negative momentum and oversold levels - tradersunion.com
TeraWulf, Viatris, MGM, Nucor, Best Buy Shake-Up - TipRanks
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight - GuruFocus
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Vanguard (VTRS) Amendment No.3: Reports 0% Beneficial Ownership After Realignment - Stock Titan
(VTRS.O) | Stock Price & Latest News - Reuters
Empowering the Front Lines: How the NCD Academy Is Transforming Community Level Care - Viatris
Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative MedicinesSlideshow (NASDAQ:VTRS) 2026-03-25 - Seeking Alpha
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Named to 3BL’s 100 Best Corporate Citizens of 2023 Ranking - CSRwire
Viatris Insider Sold Shares Worth $283,539, According to a Recent SEC Filing - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Siemens Healthineers AG (SEMHF), Viatris (VTRS) - The Globe and Mail
Top Viatris Executive Makes Notable Move With Insider Stock Sale - TipRanks
Viatris Inc officer Campbell sells $283k in shares - Investing.com
Viatris (VTRS) insider trims stake with 21,350-share open-market sale - Stock Titan
Global cardiovascular leaders convene as Viatris joins ACC26 event in New Orleans - Traders Union
Viatris sees positive top-line phase 3 results for night driving impairment asset - MSN
[144] Viatris Inc SEC Filing - stocktitan.net
Barclays raises Viatris stock price target on pipeline potential By Investing.com - Investing.com Australia
Barclays raises Viatris stock price target on pipeline potential - Investing.com
VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Viatris’ Effexor Approved in Japan for Generalized Anxiety Disorder - contractpharma.com
Barclays Adjusts Viatris Price Target to $17 From $15, Maintains Overweight Rating - marketscreener.com
Viatris Stock: Is VTRS Outperforming the Health Care Sector? - Yahoo Finance
Viatris Says Japan Regulator Approves Effexor for Generalized Anxiety Disorder in Adults - marketscreener.com
Viatris wins Japan approval for Effexor to treat anxiety disorder - Investing.com
Japan clears Effexor as first approved GAD treatment for adults - Stock Titan
Levi & Korsinsky Notifies Shareholders of Viatris Inc.(VTRS) of a Class Action Lawsuit and an Upcoming Deadline - The National Law Review
Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for Adults with Generalized Anxiety Disorder (GAD) - Bitget
How (VTRS) Movements Inform Risk Allocation Models - Stock Traders Daily
What are analysts saying about Viatris Inc (VTRS) stock? - MSN
Viatris shares break six-session winning streak - MSN
Will Viatris’ 2030 Capital Return And Growth Blueprint Change Viatris' (VTRS) Narrative - Yahoo Finance
Jefferies Keeps Their Buy Rating on Viatris (VTRS) - The Globe and Mail
Theravance's Q4 Earnings and Revenues Miss Estimates - TradingView
Viatris: Is It A Credible Turnaround Or Overly Optimistic 2030 Plan? - Seeking Alpha
Will Viatris’ 2030 Capital and R&D Framework Reset the Core Investment Narrative for VTRS? - simplywall.st
Investor Alert: Robbins LLP Informs Stockholders of the Viatris Inc. Class Action - GuruFocus
Viatris sets revenue growth targets through 2030 By Investing.com - Investing.com India
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):